Business
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
SOLANA BEACH, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the publication of new preclinical data on ART12.11, its proprietary cannabidiol:tetramethylpyrazine (CBD:TMP) cocrystal. The peer-reviewed study, conducted in collaboration with researchers at West
About this update from Artelo Biosciences, Inc.
[{"type":"image","alt":"Artelo Biosciences","displaySize":"","headline":null,"caption":"Artelo Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dtRWcM_YXYcz7bexobLzxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e","width":183,"height":80}},"lazy":false},{"type":"text","content":"SOLANA BEACH, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the publication of new preclinical data on ART12.11, its proprietary cannabidiol:tetramethylpyrazine (CBD:TMP) cocrystal.","length":433,"tagName":"p"},{"type":"text","content":"The peer-reviewed study, conducted in collaboration with researchers at Western Ontario University, was published in Progress in Neuro-Psychopharmacology and Biological Psychiatry and highlighted that ART12.11 significantly outperformed cannabidiol (CBD) alone in reducing stress-induced depression and anxiety symptoms, while also achieving superior oral bioavailability.","length":372,"tagName":"p"},{"type":"text","content":"Key Findings","length":12,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Enhanced Efficacy: ART12.11 reversed stress-induced behavioral deficits and produced robust anti-depressant and anxiolytic-like effects. These benefits were superior to CBD alone, TMP alone, or a non-crystalline mixture of CBD and TMP.","length":235,"tagName":"p"}]},{"val":[{"type":"text","content":"Improved Bioavailability: Oral administration of ART12.11 resulted in higher plasma concentrations of CBD and its major metabolite, highlighting improved pharmacokinetic properties over conventional CBD formulations.","length":216,"tagName":"p"}]},{"val":[{"type":"text","content":"Mechanistic Insights: ART12.11 enhanced activation of the endocannabinoid and serotonergic systems in brain regions critical to mood regulation, including the prefrontal cortex, ventral hippocampus, and nucleus accumbens.","length":221,"tagName"...